United Therapeutics Corporation
UTHR
$536.02
-$0.10-0.02%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 790.20M | 799.50M | 798.60M | 794.40M | 735.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 790.20M | 799.50M | 798.60M | 794.40M | 735.90M |
| Cost of Revenue | 103.40M | 100.90M | 87.60M | 92.50M | 75.90M |
| Gross Profit | 686.80M | 698.60M | 711.00M | 701.90M | 660.00M |
| SG&A Expenses | 191.80M | 181.80M | 212.50M | 170.10M | 164.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 434.70M | 410.20M | 434.10M | 411.60M | 374.00M |
| Operating Income | 355.50M | 389.30M | 364.50M | 382.80M | 361.90M |
| Income Before Tax | 444.00M | 438.00M | 408.40M | 423.50M | 396.50M |
| Income Tax Expenses | 79.70M | 99.30M | 98.90M | 101.30M | 95.20M |
| Earnings from Continuing Operations | 364.30M | 338.70M | 309.50M | 322.20M | 301.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 364.30M | 338.70M | 309.50M | 322.20M | 301.30M |
| EBIT | 355.50M | 389.30M | 364.50M | 382.80M | 361.90M |
| EBITDA | 378.30M | 411.20M | 385.60M | 402.60M | 381.60M |
| EPS Basic | 8.41 | 7.73 | 6.86 | 7.18 | 6.74 |
| Normalized Basic EPS | 5.75 | 6.18 | 5.72 | 5.97 | 5.63 |
| EPS Diluted | 7.70 | 7.16 | 6.41 | 6.63 | 6.18 |
| Normalized Diluted EPS | 5.26 | 5.72 | 5.34 | 5.51 | 5.17 |
| Average Basic Shares Outstanding | 43.30M | 43.80M | 45.10M | 44.90M | 44.70M |
| Average Diluted Shares Outstanding | 47.30M | 47.30M | 48.30M | 48.60M | 48.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |